RJVA-002

RJVA-002 is a dual agonist gene therapy targeting both the gastric inhibitory polypeptide receptor (GIPR) and the glucagon-like peptide 1 receptor (GLP-1R). It is being developed by Fractyl Health as a locally administered AAV9 viral vector that expresses human GIP and GLP-1 hormones from a human insulin promoter, specifically designed for pancreatic delivery. The therapy aims to activate both GIP and GLP-1 receptors, which play crucial roles in regulating blood sugar levels and body weight. Its primary indication is obesity, with preclinical data supporting its potential for durable metabolic control through single-dose administration[1][2][3][9].

Brand names

RJVA-002RJVA002RJVA 002

Other names

RJVA 002RJVA002RJVA-002